Erbitux (Cetuximab) — Competitive Intelligence Brief

Erbitux (Cetuximab) (Erbitux (Cetuximab)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR inhibitor (monoclonal antibody). Area: Oncology.

phase 3 EGFR inhibitor (monoclonal antibody) EGFR (Epidermal Growth Factor Receptor) Oncology Biologic

Target snapshot

Erbitux (Cetuximab) (Erbitux (Cetuximab)) — Eli Lilly and Company. Cetuximab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing tumor growth and survival signals.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Erbitux (Cetuximab) TARGET	Erbitux (Cetuximab)	Eli Lilly and Company	phase 3	EGFR inhibitor (monoclonal antibody)	EGFR (Epidermal Growth Factor Receptor)
Cetuximab (EGFR inhibitor)	Cetuximab (EGFR inhibitor)	Vanderbilt-Ingram Cancer Center	marketed	EGFR inhibitor (monoclonal antibody)	EGFR (Epidermal Growth Factor Receptor)
Cetuximab/Erbitux	Cetuximab/Erbitux	Bristol-Myers Squibb	phase 3	EGFR inhibitor (monoclonal antibody)	EGFR (Epidermal Growth Factor Receptor)
Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine	Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine	Sun Yat-sen University	phase 3	Combination therapy: EGFR inhibitor (monoclonal antibody), PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog	EGFR (nimotuzumab), PD-1 (toripalimab), DNA (cisplatin and gemcitabine)
Cetuximab wkly	Cetuximab wkly	Ludwig-Maximilians - University of Munich	phase 3	EGFR inhibitor (monoclonal antibody)	EGFR (Epidermal Growth Factor Receptor)
mAb Nimotuzumab	mAb Nimotuzumab	National Institute of Cancerología	phase 3	EGFR inhibitor (monoclonal antibody)	EGFR (Epidermal Growth Factor Receptor)
Cetuximab + concomitant boost radiotherapy	Cetuximab + concomitant boost radiotherapy	Merck KGaA, Darmstadt, Germany	phase 3	EGFR inhibitor (monoclonal antibody)	EGFR (Epidermal Growth Factor Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR inhibitor (monoclonal antibody) class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Eli Lilly and Company · 1 drug in this class
3. Ludwig-Maximilians - University of Munich · 1 drug in this class
4. Merck KGaA, Darmstadt, Germany · 1 drug in this class
5. National Institute of Cancerología · 1 drug in this class
6. Vanderbilt-Ingram Cancer Center · 1 drug in this class